<DOC>
	<DOCNO>NCT02691780</DOCNO>
	<brief_summary>This study single arm , pilot study Sorafenib patient BRAF mutation Refractory solid tumor specific sensitivity Sorafenib Avatar scan progress follow standard therapy respond standard therapy standard therapy . To investigate efficacy safety Sorafenib patient Refractory solid tumor .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Sorafenib , Subject With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Provision fully inform consent prior study specific procedure . Patients must &gt; = 19 year age BRAF mutation , Refractory solid tumor and/or specific sensitivity Sorafenib Avatar scan progress follow standard therapy respond standard therapy standard therapy . ECOG Performance status02 Have measurable evaluate disease base RECIST 1.1 determine investigator . Adequate Organ Function Laboratory value Absolute neutrophil count &gt; = 1.5 x 109/L , Hemoglobin &gt; = 9g/dL , Platelets &gt; =100x 109/L Bilirubin &lt; = 1.5 x upper limit normal AST/ALT &lt; = 2.5 X upper limit normal ( 5.0 x upper limit normal , subject liver metastasis ) Creatinine &lt; = 1.5 X UNL Patients childbearing potential use adequate contraceptive measure breast feeding must negative pregnancy test prior start dose Adequate heart function Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease &lt; = 5 year . Has know active central nervous system ( CNS ) metastases Has active infection require systemic therapy Pregnancy breast feeding Patients cardiac problem Any previous treatment Sorafenib</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>